Calea zacatechichi Schltdl. (Compositae) produces anxiolytic- and antidepressant-like effects, and increases the hippocampal activity during REM sleep in rodents.

ETHNOPHARMACOLOGICAL RELEVANCE: Calea zacatechichi is a plant with an extensive popular and ritual use in Mexico. In healthy volunteers, it induces well-being and tranquility senses, and facilitates superficial stages of sleep. However, anxiolytic, and antidepressant-like effects and changes on the sleep-waking stages have not been explored. AIM: To determine anxiolytic and antidepressant-like effects of an aqueous extract of C. zacatechichi (CZ) in rodents and to analyze their effects on hippocampal activity in the rat sleep-waking cycle. MATERIAL AND METHODS: CZ anxiolytic- and antidepressant-like effects were evaluated in several mice and rat behavioral paradigms. CZ effects on temporal distribution of sleep were described, and hippocampus EEG frequency patterns were analyzed during the sleep-waking cycle; absolute and relative powers were analyzed during Rapid Eye Movements (REM) and non-REM sleep stages. CZ chemical analysis was performed by UPLC-ESI-MS. RESULTS: CZ produced specific and robust anxiolytic- and antidepressant-like effects in mice and rats, similar to those of prototypical drugs, at doses ranging from 0.5 to 50 mg/kg. CZ at 100 mg/kg produced visible mild sedative effects in rats, associated with a significant increase in Slow Wave Sleep episodes during a 6 h recording, and enhanced fast frequencies of hippocampus (gamma-band:31-50 Hz) during REM sleep. CONCLUSION: Results could support the well-being and tranquility senses reported by healthy consumers, and to explain the oneiric content during dreams and some improvements in cognitive processes described by consumers. Anxiolytic- and antidepressant-like effects of this species, reported for first time in this study could improve some aspects of mental health.

Emotional facial expressions during REM sleep dreams.

Although motor activity is actively inhibited during rapid eye movement (REM) sleep, specific activations of the facial mimetic musculature have been observed during this stage, which may be associated with greater emotional dream mentation. Nevertheless, no specific biomarker of emotional valence or arousal related to dream content has been identified to date. In order to explore the electromyographic (EMG) activity (voltage, number, density and duration) of the corrugator and zygomaticus major muscles during REM sleep and its association with emotional dream mentation, this study performed a series of experimental awakenings after observing EMG facial activations during REM sleep. The study was performed with 12 healthy female participants using an 8-hr nighttime sleep recording. Emotional tone was evaluated by five blinded judges and final valence and intensity scores were obtained. Emotions were mentioned in 80.4% of dream reports. The voltage, number, density and duration of facial muscle contractions were greater for the corrugator muscle than for the zygomaticus muscle, whereas high positive emotions predicted the number (R2 0.601, p = 0.0001) and voltage (R2 0.332, p = 0.005) of the zygomaticus. Our findings suggest that zygomaticus events were predictive of the experience of positive affect during REM sleep in healthy women.

Cortical beta EEG oscillations related to changes in muscle tone activity during sleep in spider monkey (Ateles geoffroyi).

BACKGROUND: The physiological mechanisms that allow for sleeping in a vertical position, which is primordial for arboreal primates, have not been studied yet. METHODS: A non-invasive polysomnographic study of 6 spider monkeys (Ateles geoffroyi) was conducted. The relative beta power of the motor cortex and its linear relation with muscle tone in the facial mentalis muscle and the abductor caudae medialis muscle of the tail during wakefulness and sleep stages were calculated. RESULTS: A strong negative linear relationship (r = -.8, P = .03) was found between the relative power of the beta2 band in the left motor cortex and abductor caudae medialis muscle tone during delta sleep. CONCLUSIONS: The left motor cortex, through beta2 band activity, interacts with abductor caudae medialis muscle tonicity during delta sleep. This interaction takes part in the mechanisms that regulate the sleep postures.

El origen y las funciones de los sueños a partir de los potenciales PGO / The origin and functions of dreams based on the PGO activity

Understanding the phenomenon of sleep and dreams has fascinated humans always. However, the scientific study of sleep is relatively recent. In 1953, Aserinsky and Kleitman found that slow wave sleep (SWS) was periodically interrupted by episodes of rapid EEG activity, which are accompanied by rapid eye movements (REMs), and named this sleep phase as REM sleep. Subsequently, in 1957, Dement and Kleitman discovered that these rapid eye movements coincided with the appearance of dreams. By using animal experimental models, the subcortical mechanisms underlying REM sleep have been studied, and it has been demonstrated that this activity depends on the serotonergic activity from wakefulness, which promotes the formation of peptides that trigger certain structures of the brainstem, where cholinergic mechanisms of REM sleep are integrated. In turn, on the pontine region monophasic phasic potentials (300-400 uV) are generated that can also be recorded on the lateral geniculate body and in the occipital cortex; hence the name of ponto-geniculo-occipital waves (PGO). These potentials spread to the oculomotor system to provoke the REMs of REM sleep and possibly give rise to visual hallucinatory phenomena. Furthermore, it has been shown that certain limbic structures related to emotion and memory are activated by these potentials. This suggests that PGO waves generate mnemonic and emotional components of dreams. Several aspects of the functions of these PGO waves remains to be determined, but knowledge about the origin of brain phenomena that generate dreams has had a breakthrough from its study. In the present work we review the literature concerning the work done over PGO waves and its contribution to the knowledge of the origin and functions of dreams.

El fenómeno del sueño y de los sueños es algo que siempre ha fascinado al hombre. Sin embargo, el estudio científico del sueño es relativamente reciente. En 1953, Aserinsky y Kleitman encontraron que el sueño de ondas lentas (SOL) es interrumpido periódicamente por episodios de actividad EEG rápida, que se acompañan de movimientos oculares rápidos (MORs), y denominaron a esta fase "sueño MOR". Posteriormente, Dement y Kleitman, en 1957, descubrieron que estos movimientos oculares rápidos coinciden con la aparición de los sueños. Utilizando animales de experimentación se han estudiado los mecanismos subcorticales que subyacen al sueño MOR y se ha demostrado que éste depende de una actividad serotoninérgica de la vigilia, que promueve la formación de péptidos que ponen en marcha ciertas estructuras de la región pontina del tallo cerebral en donde se integran los mecanismos colinérgicos del sueño MOR. En la región pontina, a su vez, se generan potenciales monofásicos de alto voltaje (300-400 pV) que también pueden registrarse en el cuerpo geniculado lateral y en la corteza occipital, de allí el nombre de potenciales ponto-genículo-occipitales (PGO). Estos potenciales se propagan hacia el sistema oculomotor para provocar los MORs y posiblemente den origen a los fenómenos oníricos visuales. Además se ha demostrado que ciertas estructuras del sistema límbico, relacionadas con las emociones y la memoria, son activadas por dichos potenciales. Lo anterior sugiere que los potenciales PGO generan los componentes mnésicos y emocionales de los sueños. Quedan aún por determinarse varios aspectos sobre las funciones de estos potenciales, pero el conocimiento sobre el origen de los fenómenos cerebrales que generan los sueños ha tenido un gran avance a partir de su estudio. En el presente artículo se revisa la bibliografía concerniente a los trabajos realizados sobre los potenciales PGO y su aportación al conocimiento del origen y las funciones de los sueños.

Efectos de la melatonina sobre la macro-arquitectura del sueño en pacientes con demencia tipo Alzheimer / Melatonin effects on macro arquitecture sleep in Alzheimer's disease patients

The objective of the present study was to evaluate the 5 mg. melatonin effects on the sleep macro-architecture in eight patients with middle to moderate Alzheimer's disease (DTA). Using the polysomnography technique (PSG), we made a simple-blind, non-randomized, controlled with placebo study. The PSG was carried out according to the following order: night 1: placebo administration; night 2 and 3: continues melatonin administration. In the first night with melatonin treatment, the sleep latency to the first episode of Stage 2, Delta and REM sleep, was significantly diminished as compared with placebo (≤.05). No significant difference in total time of each sleep stage and sleep efficiency was observed. Nevertheless, a tendency to diminish the total time of nocturnal wake and increase of the total sleep time in the second night with melatonin treatment was observed. We conclude that melatonin can improve sleep in patients with middle to moderate DTA.

El objetivo del presente estudio fue determinar los efectos de 5 mg. de melatonina de liberación inmediata sobre la macro-arquitectura del sueño en ocho pacientes con diagnóstico de Demencia Tipo Alzheimer (DTA) de media a moderada. Utilizando la técnica polisomnográfica (PSG) se realizó un estudio simple ciego, no aleatorio, controlado con placebo. Los registros PSG se llevaron a cabo de la siguiente manera: Noche 1: administración de placebo; noche 2 y 3: administración continua de melatonina (5 mg). Observamos que el tratamiento con melatonina durante la primera noche de administración disminuyó significativamente la latencia de la fase 2, del sueño de ondas delta y el sueño de MOR al ser comparadas con el placebo (P ≤.05). No se observaron diferencias significativas en el tiempo total de cada fase de sueño; tampoco se observaron diferencias en la eficiencia del sueño en presencia de la melatonina. Sin embargo se observó una tendencia a la disminución del tiempo total de vigilia y un aumento del tiempo total de sueño, principalmente durante la segunda noche de tratamiento. Concluimos que la melatonina puede mejorar el sueño en pacientes con DTA de media a moderada.